## Shunsuke Tamaki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/307249/publications.pdf

Version: 2024-02-01

		516215	454577
37	959	16	30
papers	citations	h-index	g-index
38	38	38	1063
30	30	30	1003
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Prognostic Significance of Cardiac 123I-MIBG SPECT Imaging in HeartÂFailureÂPatients With PreservedÂEjection Fraction. JACC: Cardiovascular Imaging, 2022, 15, 655-668.	2.3	11
2	Phenotyping of acute decompensated heart failure with preserved ejection fraction. Heart, 2022, 108, 1553-1561.	1.2	8
3	Prognostic Impact of Echocardiographic Congestion Grade in HFpEF With and Without Atrial Fibrillation. JACC Asia, 2022, 2, 73-84.	0.5	7
4	Usefulness of the 2-year iodine-123 metaiodobenzylguanidine-based risk model for post-discharge risk stratification of patients with acute decompensated heart failure. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1906-1917.	3.3	3
5	Prognostic significance of serum chloride level in heart failure patients with preserved ejection fraction. ESC Heart Failure, 2022, 9, 1444-1453.	1.4	6
6	Association between prognosis and the use of angiotensin onverting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 1801-1811.	1.4	2
7	Minimal subphenotyping model for acute heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 2738-2746.	1.4	4
8	Prognostic significance of cardiac I-123-metaiodobenzylguanidine imaging in patients with reduced, mid-range, and preserved left ventricular ejection fraction admitted for acute decompensated heart failure: a prospective study in Osaka Prefectural Acute Heart Failure Registry (OPAR). European Heart Journal Cardiovascular Imaging, 2021, 22, 58-66.	0.5	16
9	Incremental prognostic value of cardiac metaiodobenzylguanidine imaging over the coâ€morbid burden in acute decompensated heart failure. ESC Heart Failure, 2021, 8, 1167-1177.	1.4	5
10	Prognostic value of impaired hepatoâ€renal function and liver fibrosis in patients admitted for acute heart failure. ESC Heart Failure, 2021, 8, 1274-1283.	1.4	12
11	Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure. Circulation: Heart Failure, 2021, 14, e007048.	1.6	36
12	Sex Differences in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e018574.	1.6	85
13	Distinctive prognostic factor of heart failure with preserved ejection fraction stratified with admission blood pressure. ESC Heart Failure, 2021, 8, 3145-3155.	1.4	5
14	Prognostic impact of Clinical Frailty Scale in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 3316-3326.	1.4	21
15	Prognostic Importance of Pulmonary Arterial Capacitance in Acute Decompensated Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e023043.	1.6	4
16	Prediction of sudden cardiac death in chronic heart failure patients with reduced ejection fraction by ADMIRE-HF risk score and early repolarization pattern. Journal of Nuclear Cardiology, 2020, 27, 992-1001.	1.4	7
17	Prognostic Significance of Serum Cholinesterase Level in Patients With Acute Decompensated Heart Failure With Preserved Ejection Fraction: Insights From the PURSUITâ€HFpEF Registry. Journal of the American Heart Association, 2020, 9, e014100.	1.6	37
18	Are cardiac sympathetic nerve activity and epicardial adipose tissue associated with atrial fibrillation recurrence after catheter ablation in patients without heart failure?. International Journal of Cardiology, 2020, 303, 41-48.	0.8	19

#	Article	IF	CITATIONS
19	Prognostic Importance of Right Ventricular-Vascular Uncoupling in Acute Decompensated Heart Failure With Preserved Ejection Fraction. Circulation: Cardiovascular Imaging, 2020, 13, e011430.	1.3	35
20	Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 933-937.	1.4	3
21	Prognostic value of cardiac metaiodobenzylguanidine imaging and QRS duration in implantable cardioverter defibrillator patients with and without heart failure. International Journal of Cardiology, 2019, 296, 164-171.	0.8	7
22	Prognostic Value of Calculated Plasma Volume Status in Patients Admitted for Acute Decompensated Heart Failure ― A Prospective Comparative Study With Other Indices of Plasma Volume ―. Circulation Reports, 2019, 1, 361-371.	0.4	16
23	Prognostic significance of serum cholinesterase in patients with acute decompensated heart failure: a prospective comparative study with other nutritional indices. American Journal of Clinical Nutrition, 2019, 110, 330-339.	2.2	25
24	Prediction of sudden cardiac death in patients with chronic heart failure by regional washout rate in cardiac MIBG SPECT imaging. Journal of Nuclear Cardiology, 2019, 26, 109-117.	1.4	15
25	Serial Change in Serum Chloride During Hospitalization Could Predict Heart Failure Death in Acute Decompensated Heart Failure Patients. Circulation Journal, 2018, 82, 1041-1050.	0.7	28
26	Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction ― Prospective Randomized Controlled Study ―. Circulation Journal, 2017, 81, 740-747.	0.7	34
27	Usefulness of Cardiac Metalodobenzylguanidine Imaging to Improve Prognostic Power of the Model for End-Stage Liver Disease Scoring System in Patients With Mild-to-Moderate Chronic Heart Failure. American Journal of Cardiology, 2016, 117, 1947-1952.	0.7	10
28	Risk stratification of patients with chronic heart failure using cardiac iodine $\hat{a}$ $\in$ 123 metaiodobenzylguanidine imaging: incremental prognostic value over right ventricular ejection fraction. ESC Heart Failure, 2015, 2, 116-121.	1.4	5
29	Usefulness of Cardiac Meta-lodobenzylguanidine Imaging to Identify Patients With Chronic Heart Failure and Left Ventricular Ejection Fraction <35% at Low Risk for Sudden Cardiac Death. American Journal of Cardiology, 2015, 115, 1549-1554.	0.7	14
30	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H1658-H1667.	1.5	29
31	Interleukin-16 Promotes Cardiac Fibrosis and Myocardial Stiffening in Heart Failure with Preserved Ejection Fraction. PLoS ONE, 2013, 8, e68893.	1.1	72
32	Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction. European Heart Journal, 2012, 33, 1408-1416.	1.0	41
33	Balloon type elasticity sensing for left ventricle of small laboratory animal. , 2011, 2011, 904-7.		2
34	Usefulness of Cardiac Iodine-123 Meta-Iodobenzylguanidine Imaging to Improve Prognostic Power of Seattle Heart Failure Model in Patients With Chronic Heart Failure. American Journal of Cardiology, 2011, 107, 1185-1190.	0.7	27
35	Long-term $\hat{l}^2$ -blocker therapy improves diastolic function even without the therapeutic effect on systolic function in patients with reduced ejection fraction. Journal of Cardiology, 2010, 56, 176-182.	0.8	18
36	Cardiac Iodine-123 Metaiodobenzylguanidine Imaging Predicts Sudden Cardiac Death Independently of Left Ventricular Ejection Fraction in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology, 2009, 53, 426-435.	1.2	219

## SHUNSUKE TAMAKI

#	Article	IF	CITATIONS
37	Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart, 2007, 93, 1213-1218.	1.2	71